Drug Trial Radar · NCT04921527
Chiauranib Plus Weekly Paclitaxel in Patients with Platinum-refractory or Platinum-resistant Recurrent Ovarian Cancer
Last checked: Nov 19, 2026Latest source record: Oct 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
454
Planned (sponsor's estimate)
Start
Dec 20, 2021
Primary completion
Dec 31, 2024
Study completion Jul 31, 2025
Sponsor
- Lead sponsor
- Chipscreen Biosciences, Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jun 10, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- No
- Who can join
- Female only, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This randomized, double-blind, 2-arm study will evaluate the efficacy and safety of Chiauranib plus weekly paclitaxel versus placebo plus weekly paclitaxel in patients with Platinum-refractory or Platinum-resistant Recurrent ovarian cancer.
Conditions
- Ovarian Cancer
- Relapsed or Refractory
- Chiauranib
- Paclitaxel
Interventions
chiauranibDrug
50mg orally once daily
PlaceboDrug
50mg orally once daily
PaclitaxelDrug
at the first cycle, 60mg/m2, i.v infusion on day 1, 8 and 15 ; at the begining of the second cycle, after a comprehensive assessment , investigators decide whether to increase the dosage to 80mg/m2, i.v infusion on day 1, 8 and 15 ;
Primary outcomes
What the sponsor says the trial is designed to measure.
- progression-free survival (PFS)Time frame: assessed up to 1 years
- overall survival (OS)Time frame: assessed up to 2 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Fudan University Shanghai Cancer Center
Shanghai, China, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.